AbCellera (NASDAQ:ABCL) today announced financial results for the third quarter of 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
"This was a
AbCellera (NASDAQ:ABCL) announced that the Company will present at the UBS Global Biopharma Conference on November 17, 2026.
A live audio webcast of the presentation may be accessed through a link that will be posted
AbCellera (NASDAQ:ABCL) announced that the Company will present at the following investor conferences:
Stifel Healthcare Conference, November 11, 2026
Jefferies Global Healthcare Conference in London, November
AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of
AbCellera (NASDAQ:ABCL) today announced an upcoming poster presentation of Phase 1/2 data on ABCL635 at The Menopause Society’s (TMS) 2026 Annual Meeting, to be held October 20 to 24 at the Hilton Bayfront in San
AbCellera (NASDAQ:ABCL) will announce its third quarter 2026 financial results on Monday, November 9, 2026, and hold an earnings conference call at 3:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
A live
Equity Insider News Commentary AUSTIN, Texas, Oct. 1, 2026 /CNW/ -- Towards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 billion by 2035, a compound
AbCellera (NASDAQ:ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held September 30 to October 3, 2026
NEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - Artificial intelligence has become the most talked-about tool in drug discovery, promising to compress the years and billions of dollars it
AbCellera Biologics Inc. (NASDAQ:ABCL) ("AbCellera") today announced the pricing of its oversubscribed underwritten public offering of 17,435,897 common shares at a price to the public of $9.75 per share and,
DENVER, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Planet Green Holdings (NYSEAMERICAN:PLAG), NeOnc Technologies (NASDAQ:NTHI), and Quantum Corporation (NASDAQ:QMCO) made nice runs since our midday coverage. While AbCellera
AbCellera Biologics Inc. (NASDAQ:ABCL) ("AbCellera") today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain
DENVER, Aug. 10, 2026 (GLOBE NEWSWIRE) -- (247mnn.com) — Today's market is being driven by a potent combination of corporate catalysts, clinical readouts and investor anticipation, with Socket Mobile (NASDAQ:SCKT)
AUSTIN, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - Most AI applied to drug discovery works from sequence. Two molecules that look alike in their genetic code are treated as related, and
Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe vasomotor symptoms after a single dose
ABCL635 significantly improved sleep and patient global impression of
